ABANZA

Spain - Mutilva AltaBiotechnology1 H-1B visas (FY2023)

Focus: ABANZA is a Spain-based biotechnology company founded in 2021 specializing in soft tissue fixation solutions. The company operates as a pre-revenue or early-stage biotech with limited public visibility.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About ABANZA

AI assessmentNot Hiring

No open roles listed right now. Follow ABANZA to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

0/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2021

H-1B (2023): 1 approval

Help build intelligence for ABANZA

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to join a focused biotech at formative stage in an emerging medical device/biotech niche (soft tissue fixation)
Spanish headquarters may offer alternative to US-centric pharma career track with lower cost-of-living than major biotech hubs
Early-stage company structure allows potential for broad responsibility and equity upside if technology validates

Watch Out For

No active job openings and minimal hiring footprint suggest tight or dormant growth phase—career velocity likely constrained
Pre-revenue status with no disclosed funding, publications, or clinical pipeline creates high execution risk and potential cash runway concerns
Zero clinical trial activity and absent product portfolio indicate company is either in stealth pre-clinical development or struggling to advance programs

Generated by Claude from ABANZA's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo